Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03768063 · ClinicalTrials.gov registry record · Phase 3

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

A Phase 3 study of Cancer, sponsored by Hoffmann-La Roche.

Active
Registry status
Phase 3
Development phase
1,000
Enrollment target
20
Study locations

NCT03768063 is a Phase 3 study of Cancer that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 1,000 participants, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03768063, a Phase 3 study of Cancer, is active but no longer recruiting, sponsored by Hoffmann-La Roche.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
1,000 participants
Enrollment target
20
Study locations

Study Summary

This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or combination/comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and who do not have access to the study treatment locally, may continue to receive study treatment in this extension study following roll-over from the parent study.

Conditions Studied

Cancer

Interventions

  • DRUG Bevacizumab
  • DRUG Atezolizumab
  • DRUG Vemurafenib
  • DRUG Alectinib
  • DRUG Cobimetinib

Study Locations (20)

Other

  • Institut Jules Bordet - Brussels
  • UZ Brussel - Brussels
  • Multiprofile Hospital for Active Treatment Central Onco Hospital OOD - Plovdiv
  • Pontificia Universidad Catolica de Chile - Santiago
  • Masaryk?v onkologický ústav - Brno
  • Rigshospitalet - København Ø

Massachusetts

  • Massachusetts General Hospital - Boston
  • Beth Israel Deaconess Medical Center - Boston

Colorado

  • University of Colorado Cancer Center - Aurora

Connecticut

  • Yale University School Of Medicine - Trumbull

Florida

  • Advent Health Orlando - Maitland

North Carolina

  • Carolina BioOncology Institute, PLCC - Huntersville

Pennsylvania

  • St. Luke's Cancer Care Associates - Bethlehem

Texas

  • University of Texas Health Sciences Center in San Antonio - San Antonio

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2019-02-28
Est. Completion 2028-07-05
Phase Phase 3

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03768063

The ClinicalTrials.gov registry entry for NCT03768063 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (71% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.

NCT03768063 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Massachusetts, Colorado.

Frequently Asked Questions

What is clinical trial NCT03768063 about?

NCT03768063 is a clinical study titled "A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study". This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or combination/comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent study), who ar...

What is the current status of trial NCT03768063?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2019-02-28. Estimated completion is 2028-07-05.

What conditions does trial NCT03768063 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT03768063?

The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Vemurafenib (DRUG), Alectinib (DRUG), Cobimetinib (DRUG).

Who is sponsoring clinical trial NCT03768063?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03768063 being conducted?

This trial has 20 study locations across Colorado, Connecticut, Florida, Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cancer

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.